Change over period: —
NSE · LUPIN
LUPIN LTD.
-21.6% from the 52-week high · +2.6% above the low
Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the manufacture of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 18,971 full-time employees. The firm is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The firm has presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti Inflammatory Drug therapy segments and is engaged in the Anti-TB and Cephalosporins segments. The firm along with its subsidiaries has manufacturing locations spread across India, United States of America, Mexico and Brazil with trading and other incidental and related activities extending to the global markets. Its complex generics portfolio includes Filgrastim, Pegfilgrastim, Etanercept and Albuterol and others. Its biosimilar products include Lupifil (Filgrastim), Lupifil-P (Peg-Filgrastim) and Etanercept.
The short version. LUPIN LTD. reported revenue of ₹7,827 crore for Sep 2026, up 11.1% from a year earlier. Net profit was ₹1,155 crore (down 21.9% year on year). Return on equity was 23.8% in Mar 2026. Promoter holding was 46.84% in Sep 2026, down 0.11 points over 8 quarters.
1 · The price
How has the stock traded?
LUPIN LTD. trades 21.6% below its 52-week high and 2.6% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹7,827 cr.
Sep 2026 net profit of ₹1,155 cr.
6.2 pts lower than a year earlier.
Revenue compounded at 19.3% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7827 | 8277 | 7475 | 7168 | 7048 | 6268 | 5667 | 5768 |
| Net profit | 1155 | 1415 | 1460 | 1176 | 1478 | 1219 | 773 | 855 |
| Net margin % | 14.8 | 17.1 | 19.5 | 16.4 | 21.0 | 19.4 | 13.6 | 14.8 |
| EPS (₹) | 25.26 | 30.95 | 31.94 | 25.73 | 32.36 | 26.69 | 16.92 | 18.74 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 27958 | 22708 | 20011 | 16642 | 16405 | 15163 | 15375 | 16369 |
| Net profit | 5333 | 3282 | 1914 | 430 | -1528 | 1217 | -272 | 607 |
| Net margin % | 19.1 | 14.5 | 9.6 | 2.6 | -9.3 | 8.0 | -1.8 | 3.7 |
| EPS (₹) | 116.65 | 71.88 | 42.01 | 9.45 | -33.62 | 26.81 | -6.02 | 13.4 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 23.8% in Mar 2026; debt to equity is 0.26.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 23.8 | 19.1 | 13.4 | 3.5 |
| Return on capital % | 28.4 | 21.3 | 17.6 | 7.2 |
| EBITDA margin % | 30.6 | 23.9 | 19.5 | 11.2 |
| Net margin % | 18.8 | 14.3 | 9.5 | 2.6 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 19.3% | 13.2% |
| Profit CAGR | 131.5% | 34.4% |
4 · The owners
Who holds it, and are they adding?
Down 0.11 pts over 8 quarters.
Up 1.24 pts over 8 quarters.
Down 0.96 pts over 8 quarters.
+55 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 46.95 | 46.92 | 46.9 | 46.9 | 46.89 | 46.85 | 46.85 | 46.84 | -0.11 |
| FII | 22.04 | 21.46 | 21.25 | 20.49 | 21.49 | 21.71 | 22.42 | 23.28 | +1.24 |
| DII | 24.74 | 25.41 | 25.56 | 26.55 | 25.58 | 25.32 | 24.65 | 23.78 | -0.96 |
| Public | 6.26 | 6.2 | 6.28 | 6.06 | 6.03 | 6.11 | 6.08 | 6.09 | -0.17 |
Mutual fund holdings · Oct 2026
255 schemes hold this stock
200 the month before.
- TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND7.36% of NAV
- Motilal Oswal Nifty MidSmall Healthcare Index Fund7.35% of NAV
- NIPPON INDIA PHARMA FUND6.16% of NAV
- Baroda BNP Paribas Health and Wellness Fund5.86% of NAV
- Bandhan Healthcare Fund4.95% of NAV
- Nippon India Nifty Pharma ETF4.83% of NAV
- ICICI Prudential Nifty Pharma ETF4.83% of NAV
- ICICI Prudential Nifty Pharma Index Fund4.83% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for LUPIN LTD. are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about LUPIN LTD.
What is the LUPIN LTD. share price?
LUPIN LTD. (LUPIN) last closed at ₹1,998.80, up 1.36% on the day. Its 52-week range is ₹1,922.00 to ₹2,514.80.
What is the market cap of LUPIN LTD.?
LUPIN LTD. has a market capitalisation of about ₹90,027 crore. Its price-to-earnings ratio is 16.3.
How are LUPIN LTD.'s latest results?
LUPIN LTD. reported revenue of ₹7,827 crore for Sep 2026, up 11.1% from a year earlier. Net profit was ₹1,155 crore (down 21.9% year on year). Return on equity was 23.8% in Mar 2026. Promoter holding was 46.84% in Sep 2026, down 0.11 points over 8 quarters.
Who owns LUPIN LTD.?
As of Sep 2026, shareholding was: Promoter 46.84%, FII 23.28%, DII 23.78%, Public 6.09%.
How many mutual funds hold LUPIN LTD.?
255 mutual fund schemes held LUPIN LTD. in October 2026. That compares with 200 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 25 Jul 2025 · Final Dividend - Rs. 12
- 16 Jul 2024 · Final Dividend - Rs. 8
- 14 Jul 2023 · Final Dividend - Rs. 4
- 14 Jul 2022 · Final Dividend - Rs. 4
- 27 Jul 2021 · Final Dividend - Rs. 6.5
- 03 Aug 2020 · Final Dividend - Rs. 6
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.